The DOI matches its Crossref record; 153 of the 157 references it cites were found in a registry or an index; 29 of the 42 sources its claims cite were checked for support.
Microbiome meets immunotherapy: unlocking the hidden predictors of immune checkpoint inhibitors
Open accessAbstract
Immune checkpoint inhibitors (ICIs) have revolutionized cancer immunotherapy, with the microbiome significantly influencing treatment outcomes. Analysis of 4663 studies (2014.01-2024.10) identified 71 eligible randomized controlled trials (RCTs) and cohort studies (41 viral, 30 bacterial). Analyses included subgroup assessments by cancer type, microbial taxa, and ICI regimens. Among 4663 identified studies, 71 met inclusion criteria (41 viral, 30 bacterial). Viral status, particularly hepatitis B virus (HBV) and human papillomavirus (HPV), significantly associated with ORR and DCR. Bacterial enrichment correlated with improved survival in hepatobiliary (OS: HR = 4.33, 95%CI: 2.20-8.50) and lung cancers (PFS: HR = 1.70, 95%CI: 1.04-2.78). Multi-microbiome models demonstrated superior outcome prediction, with microbial diversity correlating with improved PFS (HR = 0.64, 95%CI: 0.42-0.98). Viral status showed cancer-specific associations with SAEs. The microbiome serves as a valuable predictor of ICI outcomes. Future studies should emphasize large-scale RCTs, standardized assessment methods, and host-microbiome interactions.
Overview
CoChat Summary
TL;DR
This PRISMA meta-analysis of 71 studies (41 viral, 30 bacterial) found baseline microbiome status predicts ICI efficacy, especially viral status for ORR, with cancer- and regimen-specific effects. Bacterial enrichment and multi-microbiome models showed tumor-specific survival associations, while safety associations were limited and heterogeneous.
Key findings
- Among 71 included studies (41 viral, 30 bacterial), baseline microbiota was associated with ORR: pooled RR 1.29 (95% CI 1.07–1.55, P = 0.049, N = 34, I² = 55.6%); virus-related cohorts had RR 1.28 (95% CI 1.11–1.47, P < 0.001, N = 27, I² = 47.9%).
- Viral status predicted ORR (RR 1.36, 95% CI 1.09–1.69, P = 0.008, N = 29), with HBV RR 1.36 (95% CI 1.10–1.67, P = 0.005, N = 9) and HPV RR 1.61 (95% CI 1.19–2.18, P = 0.002, N = 7); hepatobiliary cancers RR 1.71 (95% CI 1.22–2.38, P = 0.002) and monotherapy RR 1.46 (95% CI 1.22–1.74, P < 0.001, N = 16). DCR pooled RR was 0.99 (95% CI 0.71–1.39, I² = 82.7%), but HBV was positive (RR 1.29, 95% CI 1.10–1.50, P = 0.001, N = 4) and EBV negative (RR 0.63, 95% CI 0.52–0.77, P < 0.001, N = 3).
- Bacterial enrichment was associated with OS in hepatobiliary cancers (HR 4.33, 95% CI 2.20–8.50, P < 0.001, N = 3) and PFS in hepatobiliary cancers (HR 2.33, 95% CI 1.54–3.53, P < 0.001, N = 3) and lung cancer (HR 1.70, 95% CI 1.04–2.78, P = 0.035, N = 2); gastrointestinal cancer PFS was negatively associated (HR 0.82, 95% CI 0.70–0.96, P = 0.016, N = 4). Multi-microbiome models were associated with PFS (HR 0.64, 95% CI 0.42–0.98, P = 0.039, N = 2).
- Safety: viral status was not significantly associated with overall irAEs (RR 1.04, 95% CI 0.92–1.17, P > 0.05) or SAEs (RR 1.10, 95% CI 0.57–2.25, P = 0.570, I² = 72.8%); hepatobiliary SAEs showed RR 0.62 (95% CI 0.39–1.00, P = 0.048, N = 3) and monotherapy SAEs RR 2.31 (95% CI 1.35–3.94, P = 0.002, N = 2).
Methods
- PRISMA-compliant meta-analysis registered in PROSPERO (CRD42025630951); searched PubMed, Web of Science, Medline, Embase, Cochrane Library, Wiley Online Library, ClinicalTrials.gov, and ESMO/ASCO/AACR conference abstracts from January 1, 2014, to October 9, 2024; human studies only, with no restrictions on publication type or language.
- Included RCTs or cohort studies of pathologically confirmed malignancies with in vivo microbiome profiling and associations with ICI outcomes; required ORR, DCR, PR, CR, SD, PFS, OS, or unadjusted HRs, and/or irAEs/SAEs; excluded animal studies, studies lacking pre-treatment microbiome profiles or specific microbiome classifications, and studies reporting only adjusted HRs.
- Three researchers independently screened and extracted data; quality assessed with Newcastle–Ottawa Scale for cohorts and Cochrane ROB for RCTs; publication bias assessed with funnel plots and Egger’s test; pooled RRs for ORR/DCR and HRs for PFS/OS using RevMan 5.4 and R 4.4.1, with fixed-effect models for I² < 50% and random-effect models for I² > 50%, significance at P < 0.05.
Limitations
- Stated: the analysis primarily included moderate- to high-quality cohort studies with a lack of RCTs, limiting confounding control and causal inference; endpoints were incomplete and heterogeneous across studies (viral studies lacked long-term follow-up; bacterial studies lacked AE data); bacterial presence/enrichment was often analyzed using binary classifications without standardized sequencing or categorization; sample sizes and cohorts were limited, most bacterial samples were fecal, and few were from extracellular vesicles or tumor tissues; subgroup analyses were insufficiently deep.
- Evident: many subgroup estimates relied on single cohorts (e.g., hepatobiliary DCR, melanoma/mesothelioma OS, phylum-level bacterial results), and some findings had confidence intervals whose upper bound equaled 1.0 (hepatobiliary SAEs RR 0.62, 95% CI 0.39–1.00; multiple bacterial taxa OS HR 0.54, 95% CI 0.29–1.0), requiring validation. High heterogeneity was present in some pooled analyses (DCR I² = 82.7%; SAEs I² = 72.8%; multiple bacterial communities PFS I² = 81.3%).
- Evident: publication bias tests were not statistically significant for ORR/OS/PFS, but funnel plots showed asymmetry and substantial between-study heterogeneity (τ² values), so results should be interpreted cautiously.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
21 Valid · 4 Not valid · 4 Not checked · 81 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“Furthermore, patients demonstrating response to anti-PD-1 therapy exhibited significantly enhanced clinical benefits compared to those characterized by Epstein-Barr virus progression (defined as viral DNA load exceeding 1.5-fold baseline), viral response (defined as DNA load below 0.5-fold baseline), or early clearance of plasma EBV DNA50.”
§ Microbiome meets immunotherapy: unlocking the hidden predictors of immune checkpoint inhibitors > Discussion
What the sources say
- Disputedcites [50] Lin, S. et al. Early change of plasma Epstein-Barr virus DNA load and the viral lytic genome level could positively predict clinical outcome in recurrent or metastatic nasopharyngeal carcinoma receiving anti-programmed cell death 1 monotherapy. BMC Cancer 24, 797 (2024). sourceExperimental — accuracy not yet measured
The Results section (page unavailable) reports significantly better overall survival for EBV responders than for patients with EBV progression—not better outcomes for anti-PD-1 responders than for EBV responders. The Discussion also identifies early plasma EBV DNA clearance as EBV response and associates it with superior survival, contrary to treating those patients as a poorer-outcome comparison group. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
boostedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“These findings support the hypothesis that specific viruses can enhance antitumor immune responses102.”
§ Microbiome meets immunotherapy: unlocking the hidden predictors of immune checkpoint inhibitors > Discussion
What the sources say
- Could not verifycites [102] Song, G. et al. Global immune characterization of HBV/HCV-related hepatocellular carcinoma identifies macrophage and T-cell subsets associated with disease progression. Cell Discov. 6, 90 (2020). sourceExperimental — accuracy not yet measured
The Introduction identifies HBV and HCV infection as risk factors for hepatocellular carcinoma. The Results section on intercellular communication reports increased interactions involved in antitumor responses, but attributes them partly to tumor antigens, not to viruses. Searches for viral enhancement of antitumor immunity found no passage making that connection; page numbers were unavailable in our copy. (LLM, conf=0.74)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Ho et al. compared the clinical benefits of PD-1/PD-L1 inhibitors in HCC patients with and without HBV/HCV infections, finding no significant differences in TME immune cell infiltration subtypes or immune checkpoint molecule expression levels108.”
§ Microbiome meets immunotherapy: unlocking the hidden predictors of immune checkpoint inhibitors > Discussion
What the sources say
- Partly supportedcites [108] Ho, W. J. et al. Viral status, immune microenvironment and immunological response to checkpoint inhibitors in hepatocellular carcinoma. J. Immunother. Cancer 8, e000394 (2020). sourceExperimental — accuracy not yet measured
The Results section, “Tumor immune microenvironment in HCV, HBV, and uninfected HCC” (page unavailable), reports no significant association of viral etiology with markers of several infiltrating immune-cell types or with tumor immune-checkpoint expression. But those TME findings came from TCGA tumor data, not from the patients treated with PD-1/PD-L1 inhibitors; the paper analyzed treatment responses separately. The claim incorrectly presents the TME comparison as a finding in treated patients. (LLM, conf=0.88)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Virus-associated tumor microenvironment (TME) may be related to the dynamic transformation and activity of immune cells103.”
§ Microbiome meets immunotherapy: unlocking the hidden predictors of immune checkpoint inhibitors > Discussion
What the sources say
- Partly supportedcites [103] Liu, L. et al. HPVTIMER: a shiny web application for tumor immune estimation in human papillomavirus-associated cancers. iMeta 2, e130 (2023). sourceExperimental — accuracy not yet measured
The Introduction (page unavailable) links the HPV-associated tumor immune microenvironment to altered immune-cell activation, trafficking, and abundance. It does not establish dynamic transformation over time, and its discussion is limited to HPV-associated cancers rather than virus-associated tumors generally. (LLM, conf=0.82)
hedgedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“This discrepancy may be related to the balance of inflammation and immune recognition mechanisms within the TME108,109.”
§ Microbiome meets immunotherapy: unlocking the hidden predictors of immune checkpoint inhibitors > Discussion
What the sources say
- Supportedcites [108] Ho, W. J. et al. Viral status, immune microenvironment and immunological response to checkpoint inhibitors in hepatocellular carcinoma. J. Immunother. Cancer 8, e000394 (2020). source
The Discussion (page unavailable) proposes that viral antigens may affect antitumor responses, but virus-specific T cells in HCC may not distinguish infected tumor cells from infected normal liver cells. It also contrasts virus-specific responses with underlying cirrhosis; the Background (page unavailable) identifies chronic inflammation as a likely contributor to HCV-associated HCC. Together, these passages support the citing sentence’s hedged explanation of the discrepancy. (LLM, conf=0.84)
- Not checked — no full text of the sourcecites [109] Li, X., Liu, X., Tian, L. & Chen, Y. Cytokine-mediated immunopathogenesis of Hepatitis B virus infections. Clin. Rev. Allergy Immunol. 50, 41–54 (2016). source
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on 3 assumptions not shown here.
- Supported
54 more claims · 7 with their cited sources checked
Create a free account to see all 110 claims and to verify the 2 references still open.
- It may state two separate claims as one. 42
- Probably not a substantial claim. 14
- Borderline: one of the tests for a substantial claim is unclear. 1
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Microbiome meets immunotherapy: unlocking the hidden predictors of immune checkpoint inhibitors > Discussion
“tumor tissue sampling appeared to enhance the predictive value of viral biomarkers for ORR(RR = 11.76) (95% CI: 1.33–2.33, P < 0.001, N = 8)”
§ Microbiome meets immunotherapy: unlocking the hidden predictors of immune checkpoint inhibitors > Results > Virus-associated efficacy analysis with ORR
“tissue-derived samples exhibited a pooled RR of 1.76 (95% CI: 1.33–2.33, P < 0.001, N = 8)”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Microbiome meets immunotherapy: unlocking the hidden predictors of immune checkpoint inhibitors > Results > Virus-associated efficacy analysis with DCR
“a combined RR of 0.99 (95% CI: 0.71–1.39, P < 0.001)”
§ Microbiome meets immunotherapy: unlocking the hidden predictors of immune checkpoint inhibitors > Results > Virus-associated efficacy analysis with DCR
“The pooled analysis revealed significant heterogeneity (I2 = 82.7%) and a combined RR of 0.99 (95% CI: 0.71–1.39, P < 0.001), indicating substantial variability in the predictive value of viral status for DCR, which may limit its utility as an independent prognostic marker.”
Citations
Cites
Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors
Routy, B., Le Chatelier, E., Derosa, L., Duong, C. P. M., Alou, M. T., Daillère, R., Fluckiger, A., Messaoudene, M., Rauber, C., Roberti, M. P., et al. (2018) · Science · doi:10.1126/science.aan3706 · Cited by 5,671 · cited 1×
“However,FMTfromICIrespondershasdemonstratedthe ability to restore microbial diversity and re-establish antitumor activity 139,141,142 .”
Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients
Gopalakrishnan, V., Spencer, C. N., Nezi, L., Reuben, A., Andrews, M. C., Karpinets, T. V., Prieto, P. A., Vicente, D., Hoffman, K., Wei, S. C., et al. (2018) · Science · doi:10.1126/science.aan4236 · Cited by 4,812
Self-citationCommensal Bifidobacterium promotes antitumor immunity and facilitates anti–PD-L1 efficacy
Sivan, A., Corrales, L., Hubert, N., Williams, J. B., Aquino-Michaels, K., Earley, Z. M., Benyamin, F. W., Man Lei, Y., Jabri, B., Alegre, M.-L., et al. (2015) · Science · doi:10.1126/science.aac4255 · Cited by 3,888
The impact of the gut microbiota on human health: an integrative view
Clemente, J. C., Ursell, L. K., Parfrey, L. W., & Knight, R. (2012) · Cell · doi:10.1016/j.cell.2012.01.035 · Cited by 3,710 · cited 1×
“The therapeutic effectiveness of ICIs depends on a healthy gut microbiota, which requires microbial diversity and dynamic equilibrium with the immune system 135,136 .”
Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota
Vétizou, M., Pitt, J. M., Daillère, R., Lepage, P., Waldschmitt, N., Flament, C., Rusakiewicz, S., Routy, B., Roberti, M. P., Duong, C. P. M., et al. (2015) · Science · doi:10.1126/science.aad1329 · Cited by 3,488 · cited 2×
“Preclinical studies have shown that speci fi c gut microbiota, such as Bacteroides fragilis and Bi fi dobacterium , enhance CD8 + T cell in fi ltration and effectorfunctions,improvingmelanomaresponsestoICIs 21,22 .”
Fecal microbiota transplant overcomes resistance to anti–PD-1 therapy in melanoma patients
Davar, D., Dzutsev, A. K., McCulloch, J. A., Rodrigues, R. R., Chauvin, J.-M., Morrison, R. M., Deblasio, R. N., Menna, C., Ding, Q., Pagliano, O., et al. (2021) · Science · doi:10.1126/science.abf3363 · Cited by 1,781
Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients
Baruch, E. N., Youngster, I., Ben-Betzalel, G., Ortenberg, R., Lahat, A., Katz, L., Adler, K., Dick-Necula, D., Raskin, S., Bloch, N., et al. (2021) · Science · doi:10.1126/science.abb5920 · Cited by 1,757 · cited 1×
“Furthermore, fecal microbiota transplantation (FMT) from ICI responders has shown potential to restore gut microbial balance and enhance therapeutic ef fi cacy 131 – 133 .”
Seiwert, T. Y., Burtness, B., Mehra, R., Weiss, J., Berger, R., Eder, J. P., Heath, K., McClanahan, T., Lunceford, J., Gause, C., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30066-3 · Cited by 1,745
Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma
Abou-Alfa, G. K., Lau, G., Kudo, M., Chan, S. L., Kelley, R. K., Furuse, J., Sukeepaisarnjaroen, W., Kang, Y.-K., Van Dao, T., De Toni, E. N., et al. (2022) · NEJM Evidence · doi:10.1056/evidoa2100070 · Cited by 1,576
PD-L1 as a biomarker of response to immune-checkpoint inhibitors
Doroshow, D. B., Bhalla, S., Beasley, M. B., Sholl, L. M., Kerr, K. M., Gnjatic, S., Wistuba, I. I., Rimm, D. L., Tsao, M. S., & Hirsch, F. R. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00473-5 · Cited by 1,575
Research works printed but not linked: 1
- Routy, B. et al. Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors. Science 359, 91–97 (2018). · DOI · Paper page
Cited by
Nourazarain, A., & Vaziri, Y. (2025) · Genes & Nutrition · doi:10.1186/s12263-025-00790-9 · Cited by 90
“Immuno-nutrition is a particularly active area of research, with studies focusing on how specific nutrients and dietary patterns can optimize immune responses to immunotherapy [311].”
Susiriwatananont, T., Eiamprapaporn, P., Roque, M. V., Farraye, F. A., Pearlman, A., & Chumsri, S. (2025) · Cells · doi:10.3390/cells14221779 · Cited by 21
“A meta-analysis reported that greater microbial diversity correlated with improved PFS (HR = 0.64, 95% CI 0.42–0.98), although heterogeneity across studies was high [92].”
InfluentialGuo, X., Zhang, H., Yao, L., & Ma, W. (2025) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.105076 · Cited by 10
Messina, B. M., Polizzi, A., Panuzzo, C., Belmonte, A., Angjelova, A., Fuochi, V., Annunziata, M., & Isola, G. (2025) · Life · doi:10.3390/life15121862 · Cited by 6
“Furthermore, chemotherapy or immunotherapy-induced neutropenia may reduce microbial clearance, facilitating overgrowth of dysbiotic biofilms [85].”
Zhang, Y., Chen, X., Wang, D., Zhou, X., Wang, Y., Zhang, G., & Liu, X. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1680921 · Cited by 4
Metadata
- Authors
- Huang, L., Li, Y., Zhang, C., Jiang, A., Zhu, L., Mou, W., Li, K., Zhang, J., Cui, C., Cui, X., Lin, A., Luo, P., & Wei, T.
- Affiliations
- Zhujiang Hospital (CN)
- Second Military Medical University (CN)
- Shanghai Jiao Tong University (CN)
- Sun Yat-sen University Cancer Center (CN)
- Corresponding author
- Lin, Anqi
- Luo, Peng
- Wei, Ting
- Venue
- npj Biofilms and Microbiomes
- Published
- 2025-09-02
- Volume
- 11
- Issue
- 1
- Pages
- 180-180
- ISSN
- 2055-5008 (ISSN-L)
- PMC
- PMC12405452
- OpenAlex
- W4413903278
- Cited by
- 28
- References
- 157
- Citations by year
- 2026: 21 · 2025: 7
- FWCI
- 11.50
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc-nd
- creativecommons.org/licenses/by-nc-nd/4.0 (tdm)
- creativecommons.org/licenses/by-nc-nd/4.0 (vor)
- Locations
- npj Biofilms and Microbiomes (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Guangdong Provincial Medical Science and Technology Research (B2023341)
- National Natural Science Foundation of China (82172750)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- gut microbiota, immune checkpoint inhibitors, cancer immunotherapy, treatment response prediction, hepatitis B virus, human papillomavirus, bacterial flora, hepatobiliary cancer, lung cancer, microbiome diversity, progression-free survival, overall survival, adverse events, host-microbiome interactions
- MeSH terms
- Immune Checkpoint Inhibitors, Bacteria, Humans, Immunotherapy, Neoplasms, Randomized Controlled Trials as Topic, Treatment Outcome, Microbiota
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Microbiome meets immunotherapy: unlocking the hidden predictors of immune checkpoint inhibitors. https://app.cochat.ai/papers/10.1038/s41522-025-00819-2
- The paper
- Huang, L., Li, Y., Zhang, C., Jiang, A., Zhu, L., Mou, W., Li, K., Zhang, J., Cui, C., Cui, X., Lin, A., Luo, P., & Wei, T. (2025). Microbiome meets immunotherapy: unlocking the hidden predictors of immune checkpoint inhibitors. npj Biofilms and Microbiomes. https://doi.org/10.1038/s41522-025-00819-2
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.